Lawrence Zana
Principal investigator, leads CONSEGNA PHARMA INC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$327KFederal grants as PI1 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
1 awards · $327K
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 15, 2023 | NIH | SBIR Phase I Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects. | $327K | CONSEGNA PHARMA INC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#2,820
Awards as PI#2,176
Patents#273
Companies
- CONSEGNA PHARMA INCLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.